View in EDS

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.

Saved in:
Bibliographic Details
Title: Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Authors: Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Oriol A; Institut Català d'Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain., Larocca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy., Bladé J; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain., Cavo M; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy., Rodriguez-Otero P; Clínica Universidad de Navarra, Pamplona, Spain., Leleu X; CHU de Poitiers, Poitiers, France., Nadeem O; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Hiemenz JW; Division of Hematology-Oncology, Department of Medicine, University of Florida, Gainesville, FL., Hassoun H; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Touzeau C; Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université d'Angers, Université de Nantes, Nantes, France.; Site de Recherche Intégrée sur le Cancer (SIRIC), Imaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD), Nantes, France.; Service d'hématologie Clinique, Centre Hospitalier Universitaire, Place Alexis Ricordeau, Nantes, France., Alegre A; Hospital Universitario La Princesa and Hospital Universitario Quironsalud, Madrid, Spain., Paner A; Rush University Medical Center, Chicago, IL., Maisel C; Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, TX., Mazumder A; The Oncology Institute of Hope and Innovation, Glendale, CA., Raptis A; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA., Moreb JS; Novant Health Hematology, Novant Health Forsyth Medical Center, Winston-Salem, NC., Anderson KC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Laubach JP; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Thuresson S; Oncopeptides AB, Stockholm, Sweden., Thuresson M; Oncopeptides AB, Stockholm, Sweden., Byrne C; Oncopeptides AB, Stockholm, Sweden., Harmenberg J; Oncopeptides AB, Stockholm, Sweden., Bakker NA; Oncopeptides AB, Stockholm, Sweden., Mateos MV; Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain.
Corporate Authors: HORIZON (OP-106) Investigators
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Mar 01; Vol. 39 (7), pp. 757-767. Date of Electronic Publication: 2020 Dec 09.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33296242
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Richardson+PG%22">Richardson PG</searchLink>; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Oriol+A%22">Oriol A</searchLink>; Institut Català d'Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain.<br /><searchLink fieldCode="AU" term="%22Larocca+A%22">Larocca A</searchLink>; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy.<br /><searchLink fieldCode="AU" term="%22Bladé+J%22">Bladé J</searchLink>; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Cavo+M%22">Cavo M</searchLink>; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.<br /><searchLink fieldCode="AU" term="%22Rodriguez-Otero+P%22">Rodriguez-Otero P</searchLink>; Clínica Universidad de Navarra, Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Leleu+X%22">Leleu X</searchLink>; CHU de Poitiers, Poitiers, France.<br /><searchLink fieldCode="AU" term="%22Nadeem+O%22">Nadeem O</searchLink>; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Hiemenz+JW%22">Hiemenz JW</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Florida, Gainesville, FL.<br /><searchLink fieldCode="AU" term="%22Hassoun+H%22">Hassoun H</searchLink>; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Touzeau+C%22">Touzeau C</searchLink>; Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université d'Angers, Université de Nantes, Nantes, France.; Site de Recherche Intégrée sur le Cancer (SIRIC), Imaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD), Nantes, France.; Service d'hématologie Clinique, Centre Hospitalier Universitaire, Place Alexis Ricordeau, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Alegre+A%22">Alegre A</searchLink>; Hospital Universitario La Princesa and Hospital Universitario Quironsalud, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Paner+A%22">Paner A</searchLink>; Rush University Medical Center, Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Maisel+C%22">Maisel C</searchLink>; Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, TX.<br /><searchLink fieldCode="AU" term="%22Mazumder+A%22">Mazumder A</searchLink>; The Oncology Institute of Hope and Innovation, Glendale, CA.<br /><searchLink fieldCode="AU" term="%22Raptis+A%22">Raptis A</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.<br /><searchLink fieldCode="AU" term="%22Moreb+JS%22">Moreb JS</searchLink>; Novant Health Hematology, Novant Health Forsyth Medical Center, Winston-Salem, NC.<br /><searchLink fieldCode="AU" term="%22Anderson+KC%22">Anderson KC</searchLink>; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Laubach+JP%22">Laubach JP</searchLink>; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Thuresson+S%22">Thuresson S</searchLink>; Oncopeptides AB, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Thuresson+M%22">Thuresson M</searchLink>; Oncopeptides AB, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Byrne+C%22">Byrne C</searchLink>; Oncopeptides AB, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Harmenberg+J%22">Harmenberg J</searchLink>; Oncopeptides AB, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Bakker+NA%22">Bakker NA</searchLink>; Oncopeptides AB, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Mateos+MV%22">Mateos MV</searchLink>; Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22HORIZON+%28OP-106%29+Investigators%22">HORIZON (OP-106) Investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2021 Mar 01; Vol. 39 (7), pp. 757-767. <i>Date of Electronic Publication: </i>2020 Dec 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33296242
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO.20.02259
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 757
    Titles:
      – TitleFull: Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Richardson PG
      – PersonEntity:
          Name:
            NameFull: Oriol A
      – PersonEntity:
          Name:
            NameFull: Larocca A
      – PersonEntity:
          Name:
            NameFull: Bladé J
      – PersonEntity:
          Name:
            NameFull: Cavo M
      – PersonEntity:
          Name:
            NameFull: Rodriguez-Otero P
      – PersonEntity:
          Name:
            NameFull: Leleu X
      – PersonEntity:
          Name:
            NameFull: Nadeem O
      – PersonEntity:
          Name:
            NameFull: Hiemenz JW
      – PersonEntity:
          Name:
            NameFull: Hassoun H
      – PersonEntity:
          Name:
            NameFull: Touzeau C
      – PersonEntity:
          Name:
            NameFull: Alegre A
      – PersonEntity:
          Name:
            NameFull: Paner A
      – PersonEntity:
          Name:
            NameFull: Maisel C
      – PersonEntity:
          Name:
            NameFull: Mazumder A
      – PersonEntity:
          Name:
            NameFull: Raptis A
      – PersonEntity:
          Name:
            NameFull: Moreb JS
      – PersonEntity:
          Name:
            NameFull: Anderson KC
      – PersonEntity:
          Name:
            NameFull: Laubach JP
      – PersonEntity:
          Name:
            NameFull: Thuresson S
      – PersonEntity:
          Name:
            NameFull: Thuresson M
      – PersonEntity:
          Name:
            NameFull: Byrne C
      – PersonEntity:
          Name:
            NameFull: Harmenberg J
      – PersonEntity:
          Name:
            NameFull: Bakker NA
      – PersonEntity:
          Name:
            NameFull: Mateos MV
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2021 Mar 01
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 39
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1